According to the new update on their site, the Mayo Clinic now states that "Hydroxychloroquine may be used to treat coronavirus (COVID-19) in certain hospitalized patients."
This marks a departure from their previous stance, in which the Mayo Clinic had described Hydroxychloroquine and chloroquine as "malaria drugs authorized for emergency use by the FDA during the COVID-19 pandemic." However, the FDA later withdrew that authorization after data analysis revealed that these drugs were not effective in treating COVID-19.
The Mayo Clinic's change in position is noteworthy, as it suggests that there may be a potential role for Hydroxychloroquine in the treatment of COVID-19, albeit in specific hospitalized patients. This update could have implications for the ongoing debate surrounding the use of this drug.
In the past, Hydroxychloroquine gained significant attention when President Trump announced that he had taken it after testing positive for COVID-19. However, this decision was met with criticism from some medical professionals, including Dr. Michael Ackerman, a cardiologist from the Mayo Clinic. Dr. Ackerman expressed concern that President Trump did not mention the potential side effects of Hydroxychloroquine.
Interestingly, Dr. Ackerman's perspective on COVID-19 vaccines and their alleged link to the deaths of young athletes differs. He dismissed such claims as "junk science," highlighting the importance of evidence-based research in understanding the impact of vaccines on various populations.